China's Cervical Cancer Rates Plateau but Rural and Older Women Face Growing Risks

China's cervical cancer trends show national stabilization but reveal concerning disparities as older women and rural populations face growing risks while younger urban women benefit from improved screening. Analyzing two decades of data from 22 cancer registries across China, researchers found age-standardized incidence rates tripled between 2000 and 2020, reaching a plateau after 2016. However, this national trend masks significant inequities that threaten progress toward global elimination goals.

The study published in Cancer Biology & Medicine on September 15, 2025, examined incidence and mortality trends from 2000 to 2020 and compared China's progress with other Asia-Pacific countries. Using Joinpoint regression analysis, researchers documented an average annual increase of 6.5% in cervical cancer incidence until 2016, when rates began stabilizing nationally. Urban women under 35 years showed declining incidence after 2009, likely due to improved awareness and early detection. In contrast, rural women aged 35-64 years continued to experience increases, while women aged 65 and older showed steadily rising incidence and mortality in both urban and rural areas.

When benchmarked internationally, China's progress lags behind countries like Australia and the Republic of Korea, where integrated HPV vaccination and screening programs have sharply reduced cervical cancer rates. The findings underscore the urgent need for equitable prevention strategies in China, where only about half of women aged 35-64 have been screened and less than 10% of girls have completed HPV vaccination. Persistent gaps in access, especially in rural and aging populations, limit progress toward the WHO's elimination targets.

The research team from the National Cancer Center emphasized that China's stabilization marks a critical inflection point, but the continuing age and regional disparities call for urgent policy recalibration. The study DOI 10.20892/j.issn.2095-3941.2025.0386 provides critical evidence for refining China's national cervical cancer elimination roadmap. Researchers recommend expanding school-based HPV vaccination, scaling up primary HPV testing with self-sampling options, and ensuring standardized treatment across healthcare levels to address the widening equity gap.

As China approaches the peak of its national cervical cancer burden around 2040, decisive interventions focused on system-level equity will determine whether elimination becomes achievable. Strengthening coordination between public health programs and local governments will be vital to ensure every woman receives the same standard of preventive care regardless of geographic location or age.